Literature DB >> 3033061

Effects of alpha-adrenergic stimulation and beta-adrenergic blockade on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis.

R Mastai, J Bosch, M Navasa, D Kravetz, J Bruix, C Viola, J Rodés.   

Abstract

The effects of beta-blockade with propranolol and of alpha-adrenergic stimulation with methoxamine, a powerful alpha-agonist, on azygos blood flow and on systemic and hepatic haemodynamics were investigated in 26 cirrhotic patients with portal hypertension. Beta-adrenergic blockade with propranolol (n = 12), evidenced by a significant reduction of heart rate (-17 +/- 1%, P less than 0.001) and cardiac index (-17 +/- 2%, P less than 0.001), caused a mild but significant decrease of hepatic venous pressure gradient (-10 +/- 2%, P less than 0.05) and a marked fall of azygos venous blood flow (-31 +/- 5%, P less than 0.05). Alpha-adrenergic stimulation with methoxamine (n = 14), manifested by a significant increase of mean arterial pressure (19 +/- 2%, P less than 0.001), mimicked the effects of propranolol on hepatic venous pressure gradient (-10 +/- 4%, P less than 0.05) and cardiac index (-11 +/- 2%, P less than 0.001). However, azygos blood flow was not significantly reduced by methoxamine (0.7 +/- 0.1 vs 0.6 +/- 0.1 l/min). On the contrary, hepatic blood flow was significantly reduced by methoxamine (-19 +/- 4%, P less than 0.01) but not by propranolol (-7 +/- 7%, ns). Similarly, in 8 patients who received methoxamine after being beta-blocked by propranolol, azygos blood flow, that was markedly reduced by beta-blockade, did not experience a further reduction but increased slightly by alpha-adrenergic stimulation, while hepatic blood flow, that was not reduced by propranolol, decreased significantly during the subsequent methoxamine infusion.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3033061     DOI: 10.1016/s0168-8278(87)80012-0

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  5 in total

1.  Hemodynamic effects of renin-angiotensin-aldosterone inhibitor and β-blocker combination therapy vs. β-blocker monotherapy for portal hypertension in cirrhosis: A meta-analysis.

Authors:  Jianrong Wang; Wenxia Lu; Jingjing Li; Rong Zhang; Yuqing Zhou; Qin Yin; Yuanyuan Zheng; Fan Wang; Yujing Xia; Kan Chen; Sainan Li; Tong Liu; Jie Lu; Yingqun Zhou; Chuan-Yong Guo
Journal:  Exp Ther Med       Date:  2017-03-09       Impact factor: 2.447

2.  Postprandial vascular response in patients with cirrhosis. Short-term effects of propranolol administration.

Authors:  D Alvarez; C Miguez; A Podesta; R Terg; A Sanchez Malo; J C Bandi; S Sanchez; R Mastai
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

3.  Hemodynamic and metabolic effects of terlipressin in patients with cirrhosis receiving a nonselective beta-blocker.

Authors:  F Vachiery; R Moreau; A Gadano; S Yang; P Sogni; A Hadengue; S Cailmail; T Soupison; D Lebrec
Journal:  Dig Dis Sci       Date:  1996-09       Impact factor: 3.199

4.  Carvedilol--NSBB of choice in all cirrhotics? Short title: Carvedilol for portal hypertension.

Authors:  Puneeta Tandon; Juan G Abraldes
Journal:  Saudi J Gastroenterol       Date:  2015 Sep-Oct       Impact factor: 2.485

Review 5.  Cirrhotic portal hypertension: From pathophysiology to novel therapeutics.

Authors:  Lakmie S Gunarathne; Harinda Rajapaksha; Nicholas Shackel; Peter W Angus; Chandana B Herath
Journal:  World J Gastroenterol       Date:  2020-10-28       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.